Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/4/2022 | $25.00 → $3.50 | Buy → Neutral | Goldman |
| 4/1/2022 | $25.00 → $1.80 | Outperform → Mkt Perform | SVB Leerink |
| 4/1/2022 | $32.00 → $6.00 | Buy → Hold | Stifel |
| 4/1/2022 | Buy → Neutral | H.C. Wainwright | |
| 11/12/2021 | $42.00 → $25.00 | Outperform | SVB Leerink |
| 8/16/2021 | $46.00 → $49.00 | Outperform | SVB Leerink |
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
Goldman downgraded Silverback Therapeutics from Buy to Neutral and set a new price target of $3.50 from $25.00 previously
SVB Leerink downgraded Silverback Therapeutics from Outperform to Mkt Perform and set a new price target of $1.80 from $25.00 previously
Stifel downgraded Silverback Therapeutics from Buy to Hold and set a new price target of $6.00 from $32.00 previously